Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACA | Q13085 | 16/20 | 0.72 |
| ▸ | ACACB | O00763 | 9/20 | 0.72 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.52 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19834345 | 1.00 | ACACA (0.72) | ACACAACACBMTNR1AMTNR1B | |
| SCHEMBL19834545 | 0.90 | ACACA (0.76) | ACACAACACBMTNR1AMTNR1B | |
| SCHEMBL19834543 | 0.90 | ACACA (0.76) | ACACAACACBMTNR1AMTNR1B | |
| SCHEMBL19834483 | 0.90 | ACACA (0.72) | ACACAACACBMTNR1AMTNR1B | |
| SCHEMBL19971765 | 0.90 | ACACA (0.72) | ACACAACACBMTNR1AMTNR1B | |
| SCHEMBL19834383 | 0.89 | ACACA (0.73) | ACACAACACBMTNR1AMTNR1B | |
| SCHEMBL19834382 | 0.89 | ACACA (0.73) | ACACAACACBMTNR1AMTNR1B | |
| SCHEMBL19834379 | 0.87 | ACACA (0.72) | ACACAACACB | |
| SCHEMBL19834334 | 0.84 | ACACA (1.00) | ACACAACACB | |
| SCHEMBL19834419 | 0.84 | ACACA (0.68) | ACACAACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10252997-B2 | Monocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-04-09 | — | — | US | disclosed |
| US-10252997-B2 | Monocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-04-09 | — | — | US | disclosed |
| US-20180079723-A1 | MONOCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-22 | — | — | US | disclosed |
| US-20180079723-A1 | MONOCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-22 | — | — | US | disclosed |
| US-20180079723-A1 | MONOCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10252997-B2 | Monocyclic compound | FABP1, CPT1A, GOT2 | ACACA 58/4885ACACB 28/4885MTNR1A 995/4885 |
| US-20180079723-A1 | MONOCYCLIC COMPOUND | FABP1, CPT1A, GOT2 | ACACA 58/4885ACACB 28/4885MTNR1A 995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.